Nephrotic syndrome after oral bisphosphonate (alendronate) administration in a patient with osteoporosis

Osteoporosis International

Volumn 23, Issue 7, 2012, Pages 2059-2062

  Yilmaz, M ^a   Taninmis, H ^b   Kara, E ^b   Ozagari, A ^b   Unsal, A ^b  

^a BAKIRKOY DR SADI KONUK TRAINING AND RESEARCH HOSPITAL   (Turkey)

^b SISLI ETFAL TRAINING AND RESEARCH HOSPITAL   (Turkey)

Author keywords

Alendronate; Bisphosphonate syndrome; Nephrotic; Side effect

Indexed keywords

ALENDRONIC ACID; CREATININE; DIURETIC AGENT; VITAMIN D;

ADULT; ARTICLE; CASE REPORT; CREATININE BLOOD LEVEL; DIURETIC THERAPY; DRUG WITHDRAWAL; EDEMA; HUMAN; HUMAN TISSUE; HYPERCHOLESTEROLEMIA; HYPOALBUMINEMIA; KIDNEY BIOPSY; MALE; MESANGIUM CELL; MICROSCOPY; NEPHROTIC SYNDROME; OSTEOPOROSIS; PRIORITY JOURNAL; PROTEINURIA; SIDE EFFECT; WEIGHT GAIN; WEIGHT REDUCTION;

ADULT; ALENDRONATE; BONE DENSITY CONSERVATION AGENTS; HUMANS; MALE; NEPHROTIC SYNDROME; OSTEOPOROSIS;

EID: 84863577521     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-011-1836-2     Document Type: Article

References (17)

1. Rogers MJ, Gordon S, Benford HL, Coxon FP, Luckman SP, Monkkonen J, Frith JC (2000) Cellular andmolecularmechanisms of action of bisphosphonates. Cancer 88:2961-2978.
2. Cardwell CR, Abnet CC, Cantwell MM, Murray LJ (2010) Exposure to oral bisphosphonates and risk of esophageal cancer. JAMA 304:657-663.
3. Mundel P, Shankland SJ (2002) Podocyte biology and response to injury. J Am Soc Nephrol 13:3005-3015.
4. Kerjaschki D (2001) Caught flat-footed: podocyte damage and the molecular bases of focal glomerulosclerosis. J Clin Investig 108:1583-1587.
5. Miura N, Mizuno N, Aoyama R, Kitagawa W, Yamada H, Nishikawa K, Imai H (2009) Massive proteinuria and acute renal failure after oral bisphosphonate (alendronate) administration in apatient with focal segmental glomerulosclerosis. Clin Exp Nephrol 13:85-88.
6. Pascual J, Torrealba J, Myers J, Tome S, Samaniego M, Musat A, Djamali A (2007) Collapsing focal segmental glomerulosclerosis in a liver transplant recipient on alendronate. Osteoporos Int 18:1435-1438.
7. Stratton JD, Warwicker P (2002) Relapse of nephrotic syndrome triggered by biphosphonates. Nephrol Dial Transplant 17:1856-1857.
8. Barri YM, Munshi NC, Sukumalchantra S, Abulezz SR, Bonsib SM, Wallach J, Walker PD (2004) Podocyte injury associated glomerulopathies induced by pamidronate. Kidney Int 65:634-641.
9. Markowitz GS, Appel GB, Fine PL, Fenves AZ, Loon NR, Jagannath S, Kuhn JA, Dratch AD, D'Agati VD (2001) Collapsing focal segmental glomerulosclerosis following treatment with highdose pamidronate. J Am Soc Nephrol 12:1164-1172.
10. Tanvetyanon T, Stiff PJ (2006) Management of the adverse effects associated with intravenous bisphosphonates. Ann Oncol 17:897-907.
11. Banerjee D, Asif A, Striker L, Preston RA, Bourgoignie JJ, Roth D (2003) Short-term, high dose pamidronate-induced acute tubular necrosis: the postulated mechanisms of bisphosphonate nephrotoxicity. Am J Kidney Dis 41:1-6.
12. Janssen van Doorn K, Neyns B, Van der Niepen P, Verbeelen D (2001) Pamidronate-related nephrotoxicity (tubulointerstitial nephritis) in a patient with osteolytic bonemetastases. Nephron 89:467-468.
13. Bounameaux HM, Schifferli J, Montani JP, Jung A, Chatelanat F (1983) Renal failure associated with intravenous diphosphonates. Lancet 1:471.
14. Buysschaert M, Cosyns JP, Barreto L, Jadoul M (2003) Pamidronate-induced tubulointerstitial nephritis with Fanconi syndrome in a patient with primary hyperparathyroidism. Nephrol Dial Transplant 18:826-829.
15. Yates AJ, Percival RC, Gray RE, Atkins RM, Urwin GH, Hamdy NA, Preston CJ, Beneton MN, Russell RG, Kanis JA (1985) Intravenous clodronate in the treatment and retreatment of Paget's disease of bone. Lancet 1:1474-1477.
16. Dumon JC, Magritte A, Body JJ (1991) Efficacy and safety of the bisphosphonate tiludronate for the treatment of tumor-associated hypercalcemia. Bone Miner 15:257-266.
17. Khosla S (2010) Update in male osteoporosis. J Clin Endocrinol Metab 95:3-10